NeuBase Therapeutics, Inc. Common Stock
NBSE
NBSE was delisted on the 10th of May, 2024.
49 hedge funds and large institutions have $51.5M invested in NeuBase Therapeutics, Inc. Common Stock in 2020 Q2 according to their latest regulatory filings, with 30 funds opening new positions, 12 increasing their positions, 2 reducing their positions, and 6 closing their positions.
500% more repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 2
400% more first-time investments, than exits
New positions opened: 30 | Existing positions closed: 6
167% more capital invested
Capital invested by funds: $19.3M → $51.5M (+$32.3M)
96% more funds holding
Funds holding: 25 → 49 (+24)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$7.37M |
| 2 |
Renaissance Technologies
New York
|
+$4.31M |
| 3 |
Millennium Management
New York
|
+$3.31M |
| 4 |
GC
Greenlight Capital
New York
|
+$3.05M |
| 5 |
State Street
Boston,
Massachusetts
|
+$2.08M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
-$2.64M |
| 2 |
Squarepoint
New York
|
-$449K |
| 3 |
EI
EAM Investors
Solana Beach,
California
|
-$150K |
| 4 |
Jane Street
New York
|
-$121K |
| 5 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
-$87K |
NBSE Hedge Fund Activity: Q2 2020 in Review
49 of the 4,877 institutional investors tracked by Wall St. Rank reported a position in NeuBase Therapeutics, Inc. Common Stock (NBSE) for Q2 2020, worth a combined $51.5M — up 167% from $19.3M a quarter earlier.
Buyers outnumbered sellers: 30 funds opened new NBSE positions and 6 closed out — a net gain of 24 holders — while 12 added to existing stakes and 2 trimmed.
The largest buyer was BlackRock, adding an estimated $7.37M. The largest seller was OrbiMed, exiting entirely with an estimated $2.64M sold.
- 49 institutional investors held NeuBase Therapeutics, Inc. Common Stock (NBSE) as of Q2 2020, up from 25 in Q1 2020.
- Funds reported $51.5M of NeuBase Therapeutics, Inc. Common Stock stock for Q2 2020, up 167% quarter-over-quarter.
- 30 funds opened new NeuBase Therapeutics, Inc. Common Stock positions in Q2 2020 and 6 closed out, a net change of +24 holders.
- The largest NeuBase Therapeutics, Inc. Common Stock buyer in Q2 2020 was BlackRock, an estimated $7.37M added.
- The largest NeuBase Therapeutics, Inc. Common Stock seller in Q2 2020 was OrbiMed, an estimated $2.64M sold.
Based on aggregated 13F filings for Q2 2020.